SCHEMBL2681748

SCHEMBL2681748

Nc1ncc(-c2ccco2)cc1-c1nc2ccccc2[nH]1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK1 P06493 3/20 0.70
CDK2 P24941 3/20 0.70
MKNK1 Q9BUB5 3/20 0.70
MKNK2 Q9HBH9 3/20 0.70
PDPK1 O15530 1/20 0.70
ALOX5 P09917 1/20 0.50
EPHX2 P34913 1/20 0.50
ALDH1A1 P00352 9/20 0.47
HPGD P15428 8/20 0.47
HSD17B10 Q99714 7/20 0.47
KDM4E B2RXH2 6/20 0.47
USP2 O75604 2/20 0.47
TSHR P16473 1/20 0.47
HTT P42858 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
ATR Q13535 3/20 0.47
SMN1; SMN2 Q16637 6/20 0.47
NPC1 O15118 6/20 0.47
RAB9A P51151 6/20 0.47
MAPT P10636 4/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5117922 0.82 CDK1 (1.00) CDK1CDK2MKNK1MKNK2PDPK1
Hydrochloric Acid SCHEMBL5116173 0.81 CDK1 (0.97) CDK1CDK2MKNK1MKNK2PDPK1
SCHEMBL2682848 0.81 CDK1 (0.73) CDK1CDK2MKNK1MKNK2PDPK1
SCHEMBL2682567 0.79 CDK1 (0.79) CDK1CDK2MKNK1MKNK2PDPK1
SCHEMBL2680638 0.79 CDK1 (0.79) CDK1CDK2MKNK1MKNK2PDPK1
SCHEMBL2681945 0.79 CDK1 (0.83) CDK1CDK2MKNK1MKNK2PDPK1
SCHEMBL2682556 0.77 CDK1 (0.75) CDK1CDK2MKNK1MKNK2PDPK1
SCHEMBL2681176 0.77 CDK1 (0.79) CDK1CDK2MKNK1MKNK2PDPK1
SCHEMBL2681744 0.76 CDK1 (0.70) CDK1CDK2MKNK1MKNK2PDPK1
SCHEMBL5120432 0.76 CDK1 (0.72) CDK1CDK2MKNK1MKNK2PDPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8648201-B2 Aminopyridine derivatives for treating tumors and inflammatory diseases MERCK PATENT GMBH (DE) 2014-02-11 US claimed
US-20120115861-A1 AMINOPYRIDINE DERIVATIVES FOR TREATING TUMORS AND INFLAMMATORY DISEASES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2012-05-10 US claimed
EP-2454253-B1 AMINOPYRIDINE DERIVATIVES FOR TREATING TUMORS AND INFLAMMATORY DISEASES MERCK PATENT GMBH (DE) 2015-01-21 EP disclosed
US-8648201-B2 Aminopyridine derivatives for treating tumors and inflammatory diseases MERCK PATENT GMBH (DE) 2014-02-11 US disclosed
US-8648201-B2 Aminopyridine derivatives for treating tumors and inflammatory diseases MERCK PATENT GMBH (DE) 2014-02-11 US disclosed
US-20120115861-A1 AMINOPYRIDINE DERIVATIVES FOR TREATING TUMORS AND INFLAMMATORY DISEASES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2012-05-10 US disclosed
US-20120115861-A1 AMINOPYRIDINE DERIVATIVES FOR TREATING TUMORS AND INFLAMMATORY DISEASES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2012-05-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120115861-A1 AMINOPYRIDINE DERIVATIVES FOR TREATING TUMORS AND INFLAMMATORY DISEASES PDK1, PDK2, PDK4 CDK1 15/4885CDK2 10/4885MKNK1 782/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.